Welcome to our dedicated page for Nexalin Tech SEC filings (Ticker: NXL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Nexalin Technology, Inc. (Nasdaq: NXL) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents offer detailed information about Nexalin’s capital markets activity, governance, and material events related to its development and commercialization of non-invasive neurostimulation medical devices.
Through this page, users can review Form 8-K current reports describing events such as amendments to equity distribution agreements, at-the-market (ATM) offering programs, and changes in executive leadership or compensation arrangements. For example, Nexalin has reported an amendment to its equity distribution agreement that governs sales of common stock under a shelf registration statement on Form S-3, as well as the expiration and delisting of certain warrants while its common stock continues to trade under the NXL symbol.
Filings also include Form 25 notifications, such as the removal of specific warrant classes from listing on the Nasdaq Stock Market, and other exhibits that document legal opinions, material contracts, and related items. Together, these records help investors understand how Nexalin finances its operations, manages its securities, and responds to exchange listing requirements.
On Stock Titan, Nexalin’s filings are updated in near real time from the SEC’s EDGAR system. AI-powered tools summarize lengthy documents, highlight key sections, and make it easier to identify information about equity offerings, listing status changes, and other material developments. Users can quickly scan for relevant items across Nexalin’s 8-Ks, registration statements, and related exhibits without reading every page of the original filings.
Nexalin Technology, Inc. received a notice from Nasdaq on January 21, 2026 stating that its common stock no longer meets the minimum $1.00 bid price requirement for continued listing on The Nasdaq Capital Market. This non-compliance is based on the stock’s closing bid price over the last 30 consecutive business days.
The company has 180 calendar days, until July 20, 2026, to regain compliance by having its closing bid price at or above $1.00 per share for at least ten consecutive business days. If it fails to do so, it may qualify for a second 180-day period if it meets other Nasdaq initial listing standards apart from the bid price. If compliance is not regained, Nasdaq may move to delist the stock, although the company could appeal and would expect trading to move to an OTC Markets Group marketplace. Nexalin plans to monitor its stock price and evaluate options to regain compliance.
Nexalin Technology (NXL) filed its Q3 2025 report, highlighting continued operating losses and a going concern warning. Revenue was $18,149 for the quarter, down from $36,031 a year ago, as legacy licensing and equipment sales remained modest. Net loss for Q3 was $2,276,311 versus $2,448,257 in Q3 2024. For the nine months, revenue totaled $129,752 and net loss reached $5,845,635.
Liquidity and capital: Cash and cash equivalents were $590,075 with short‑term investments of $3,762,602, supporting total current assets of $4,817,378 against current liabilities of $357,524. Stockholders’ equity rose to $4,768,416, aided by 2025 equity issuances, including a May/June public offering of 4,090,000 shares with gross proceeds of $5,317,000. The company amended its equity distribution agreement in October to permit ATM sales up to $10,000,000; as of October 15, $4,273,859 remained available under baby shelf limits and 157,000 shares had been sold.
Operations and R&D: Operating expenses were $2,359,832 in Q3, driven by SG&A, salaries, and stock‑based compensation. The company disclosed a substantial accumulated deficit of $90,490,866 and stated there is substantial doubt about its ability to continue as a going concern. On the regulatory front, the FDA accepted a Q‑Submission in October for the Gen‑2 SYNC system targeting Alzheimer’s and dementia, enabling a formal meeting later this year.
Nexalin Technology filed a prospectus supplement for an at-the-market offering of up to $4,273,859 in gross proceeds of common stock, to be sold from time to time through Maxim Group LLC as sales agent under an existing equity distribution agreement.
The filing relies on Form S-3 General Instruction I.B.6, which caps primary sales at one-third of public float. The company reports an estimated public float of $28,772,576 based on 18,189,606 shares outstanding as of September 30, 2025 (with 2,720,479 held by affiliates) and an October 8, 2025 closing price of $1.86. Nexalin has sold approximately $5,317,000 in the past 12 months under I.B.6, leaving $4,273,859 available under this supplement and the Sales Agreement. Shares trade on Nasdaq as NXL; the last reported price on October 14, 2025 was $1.29 per share.
Nexalin Technology, Inc. amended its equity distribution agreement with Maxim Group LLC to expand its at-the-market offering capacity. The amendment increases the aggregate offering price from $3,100,000 to up to $10,000,000 under the ATM Program, allowing the company to sell common stock from time to time through the agent.
As of October 15, 2025, approximately $4,273,859 in aggregate amount of shares remained available for sale under the ATM Program. Sales, if any, will be made pursuant to the company’s effective Form S-3 shelf and a new prospectus supplement dated October 15, 2025.
Nexalin Technology, Inc. (NXL) Form 4 shows Director Leonard Osser (with spouse Marilyn Elson) reported a non-derivative acquisition of 83,333 common shares on 09/29/2025 at a recorded price of $0. After the transaction the reporting parties beneficially own 1,618,577 shares, held directly with shared voting and dispositive power between Mr. Osser and Ms. Elson. The filing is a joint ownership Form 4 and is signed by both reporting persons.
Benjamin Hu, a director of Nexalin Technology, Inc. (NXL), reported the acquisition of 36,459 shares on 09/29/2025. The Form 4 shows the transaction as an acquisition (Code A) with a reported price of $0, and that Mr. Hu now beneficially owns 377,095 shares in total. The filing breaks down those holdings as 372,929 shares held individually by Mr. Hu, 3,582 shares held jointly with his spouse Amy Lun Hu, and 584 shares held jointly with his son David D. Hu. The form is signed by Benjamin Hu on 09/30/2025.
Alan Kazden, a director of Nexalin Technology, Inc. (NXL), reported acquiring additional common stock on 09/29/2025. The Form 4 shows he acquired 36,459 shares with a reported price of $0 and, following the transaction, beneficially owns 119,590 shares. The filing states those shares are held indirectly by the Alan and Natalie Kazden Family Trust and that the reporting person has dispositive and voting control.
The submission is a routine Section 16 disclosure of an ownership change and is signed by Alan Kazden on 09/30/2025. No derivatives, option grants, dispositions, or other transaction types are reported on this Form 4.
Nexalin Technology, Inc. reported material operational and governance details showing continued cash consumption alongside recent equity raises and Nasdaq compliance. The company lost $7.8 million from operations in 2024 and generated negative operating cash flow of $3.94 million, though it reported a working capital surplus of approximately $3.4 million. Shares outstanding increased to 13,303,523 from 7,436,562, including issuance of 3,000,000 shares to investors for net proceeds of $4.52 million and multiple share issuances to Wider and consultants for services and R&D.
The filing discloses internal control weaknesses: insufficient segregation of duties in financial reporting and inadequate IT user/superuser access controls. The company invested $96,000 in a joint venture accounted for under the equity method and wrote off a previously defaulted promissory note principal of $500,000. On July 23, 2024 Nasdaq confirmed compliance with the Minimum Stockholder Equity Rule.
Nexalin Technology, Inc. reports that its publicly traded warrants issued as part of its initial public offering have expired. On September 22, 2025, at 5:00 PM Eastern time, these warrants, each exercisable for one share of common stock at an exercise price of $4.15, terminated in accordance with their original terms.
The Nasdaq Stock Market filed a Form 25 with the SEC to reflect that the warrants had expired and were delisted. The company’s common stock is unaffected by this change and will continue to trade on the Nasdaq Capital Market under the symbol NXL.
Nexalin Technology, Inc. (symbol NXLIW) is the subject of a Form 25 notification filed under the Securities Exchange Act to remove a class of its securities from listing and/or registration on the Nasdaq Stock Market LLC. The filing names the issuer and provides its principal office at 1776 Yorktown, Suite 550, Houston, Texas 77056 and a contact telephone number as listed in the form.
The document duplicates the regulatory checkboxes for rule provisions governing removal and states that Nasdaq certifies it has complied with the applicable procedures to strike or withdraw the class of securities. The form includes the standard OMB approval legend and a note that the Form 25 and attached notice comply with the applicable rules.